Notizie e Video - SEAGEN INC.

J.P. Morgan Life Sciences Private Capital Team Adds Healthcare Veteran and Past Seagen CEO David Epstein to Advisory Board PR Newswire NEW YORK, Feb. 27, 2024 NEW YORK , Feb. 27, 2024 /PRNewswire/ -- J.P. Morgan Life Sciences Private Capital today announced the addition of David Epstein to its Healthcare Advisory Board. Mr. Epstein was CEO of Seagen before closing its sale to Pfizer in December 2023 . David previously served as Executive Partner at Flagship Pioneering as well as CEO of Novartis...

Seagen Inc. (Nasdaq: SGEN) today announced that the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA ® (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla ® ) met its primary endpoint of progression-free survival (PFS). Patients in the trial had unresectable locally advanced or metastatic human epidermal growth factor receptor 2-positive (HER2-positive) breast cancer and had received previous treatment with a taxane and trastuzumab.​ Overall survival...

Seagen Inc. (Nasdaq:SGEN) (Seagen or the Company) reported financial results today for the second quarter ended June 30, 2023, highlighting record net product sales, with significant year-over-year growth of 26 percent. David Epstein, Chief Executive Officer of Seagen said, “I am pleased to report an exceptional quarter with strong performance and growth seen across our commercial portfolio. We remain focused on optimizing the potential of our commercial portfolio, advancing our innovative...

Seagen Inc. (Nasdaq: SGEN) today announced that it will report its second quarter 2023 financial results on Wednesday, August 2, 2023. Given the previously announced agreement to be acquired by Pfizer Inc., Seagen will not be hosting a conference call. About Seagen Founded 25 years ago, Seagen Inc. is a global biotechnology company that discovers, develops, manufactures and commercializes targeted cancer therapeutics, with antibody-drug conjugates (ADCs) at our core. Our colleagues work together...

Seagen Inc. (NASDAQ: SGEN) today announced that the clinical research cooperative German Hodgkin Study Group (GHSG) presented results showing that a phase 3 trial of ADCETRIS ® in combination with chemotherapy – a regimen called BrECADD (brentuximab vedotin [ADCETRIS], etoposide, cyclophosphamide, doxorubicin [Adriamycin], dacarbazine, and dexamethasone) – met its co-primary endpoints of non-inferior efficacy and superior tolerability versus a highly efficacious yet chemotherapy-intense...

Seagen Inc. (NASDAQ: SGEN) today announced an update to the U.S. Prescribing Information (PI) for ADCETRIS ® (brentuximab vedotin) to include six-year overall survival results from the phase 3 ECHELON-1 clinical trial of ADCETRIS plus combination chemotherapy in patients with previously untreated Stage III or IV classical Hodgkin lymphoma compared to chemotherapy alone. The statistically significant data were presented last year at the annual meetings of the American Society of Clinical...

Seagen Inc. (NASDAQ: SGEN) today announced updated efficacy and safety results from Part C of a phase 2 single-arm trial (SGN35-027) evaluating the antibody-drug conjugate ADCETRIS ® (brentuximab vedotin) in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine (AN+AD) for the frontline treatment of patients with early-stage classical Hodgkin lymphoma (cHL). Data results will be presented at the 17 th International Conference on Malignant...

Following a special meeting of its stockholders, Seagen Inc. (Nasdaq: SGEN) today announced that its stockholders voted to approve a proposal to adopt the previously announced merger agreement under which Pfizer will acquire Seagen for $229 per share in cash. More than 99% of the shares voted at the meeting, representing approximately 88% of the shares of Seagen common stock issued and outstanding as of the record date for the special meeting, were voted in favor of the proposal to adopt the...

Seagen Inc. (Nasdaq:SGEN) (Seagen or the Company) reported financial results today for the first quarter ended March 31, 2023. The Company also highlighted performance across its approved product portfolio, development accomplishments, and progress across its differentiated oncology pipeline of innovative ADCs and targeted therapies. “Seagen delivered strong performance in the first quarter, with significant growth of 22 percent for both total revenue and net product sales, compared to 2022,...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Seagen Inc. (NasdaqGS: SGEN) to Pfizer Inc. (NYSE: PFE). Under the terms of the proposed transaction, shareholders of Seagen will receive $229 in cash for each share of Seagen that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the...

Seagen Inc. (Nasdaq: SGEN) today announced the presentation of 17 abstracts at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023, in Chicago. Data will be presented across Seagen's portfolio of approved medicines and pipeline agents in a range of cancer types and in earlier lines of therapy. “Seagen has worked towards revolutionizing cancer care for 25 years by linking scientific innovation to meaningful impacts in patients’ lives,”...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Seagen Inc. (NASDAQ: SGEN) to Pfizer Inc. for $229.00 in cash per share is fair to Seagen shareholders. Halper Sadeh encourages Seagen shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected] . The investigation concerns whether Seagen and its board of directors violated the federal...

Seagen Inc. (Nasdaq: SGEN) today announced that it will report its first quarter 2023 financial results on Thursday, April 27, 2023. Given the recently announced agreement to be acquired by Pfizer Inc., Seagen will not be hosting a conference call. About Seagen Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has...

Seagen Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE:4503) today announced the U.S. Food and Drug Administration (FDA) has granted PADCEV ® (enfortumab vedotin-ejfv) with KEYTRUDA ® (pembrolizumab) accelerated approval in the U.S. as a combination therapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC) who are not eligible to receive cisplatin-containing chemotherapy. This indication is approved under accelerated approval based on tumor...

Seagen Inc. (Nasdaq: SGEN) today announced the presentation of 17 abstracts featuring new clinical and preclinical data at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place in Orlando from April 14-19, 2023. The broad range of data being presented at this year’s meeting includes research from Seagen’s approved medicines, as well as data from early-stage clinical, preclinical, and discovery research programs. “Seagen’s robust presence at AACR this...

...

SHAREHOLDER ALERT: Weiss Law Investigates Seagen Inc. PR Newswire NEW YORK, March 14, 2023 NEW YORK , March 14, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Seagen Inc. ("Seagen" or the "Company") (NASDAQ: SGEN) in connection with the proposed acquisition of the Company by Pfizer Inc. (NYSE: PFE). Under the terms of the merger agreement, the Company's shareholders will receive $229.00 in cash for each...

STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Seagen, Inc. - SGEN PR Newswire NEW YORK, March 14, 2023 NEW YORK , March 14, 2023 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City , is investigating Seagen,...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Seagen Inc. (NasdaqGS: SGEN) to Pfizer Inc. (NYSE: PFE). Under the terms of the proposed transaction, shareholders of Seagen will receive $229 in cash for each share of Seagen that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the...

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Seagen Inc. PR Newswire NEW YORK, March 13, 2023 NEW YORK , March 13, 2023 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Seagen Inc. (NASDAQ: SGEN) and its board of directors concerning the proposed acquisition of the company by Pfizer Inc. (NYSE: PFE). Stockholders will receive $229.00 for each share of Seagen stock that they hold. The transaction is valued at approximately $43 billion and...